Drug Trial Radar · NCT04990037
A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma
Last checked: Nov 20, 2026Latest source record: Jun 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Jul 19, 2021
Primary completion
May 30, 2023
Study completion Jun 15, 2023
Sponsor
- Lead sponsor
- Cantargia ABIndustry
- Sponsor type
- Industry
- First posted
- Aug 4, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will consider the safety and effectiveness of a study drug, CAN04, in combination with FOLFIRINOX, in the treatment of metastatic pancreatic ductal adenocarcinoma.
Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
CAN04Drug
Administered intravenously
FOLFIRINOXDrug
Administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of TEAEs (Treatment-emergent adverse events)Time frame: From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.
- Number of participants with DTLs (dose-limiting toxicities)Time frame: Up to day 28
- Number of subjects with 1 or more TEAEs leading to dose modificationsTime frame: From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.
- Number of subjects with grade ≥ 3 TEAEsTime frame: From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.
- Percentage of subjects with grade ≥ 3 TEAEsTime frame: From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.
- Number of subjects with 1 or more TEAEs leading to treatment discontinuationTime frame: From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.
- Percentage of subjects with 1 or more TEAEs leading to dose modificationTime frame: From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.
- Percentage of subjects with 1 or more TEAEs leading to treatment discontinuationTime frame: From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.
- Number of subjects with 1 or more SAEs (serious adverse events)Time frame: From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.
- Percentage of subjects with 1 or more SAEsTime frame: From the first dose until the last subject has completed their end of trial visit or the last enrolled subject has completed 6 months of treatment, whichever comes first.
Locations
9 sites in 2 countries. Site status is shown where the registry gives one.
EDOG - Institut Bergonie - PPDS
Bordeaux, France
EDOG Institut de Cancerologie de l'Ouest - PPDS
Nantes, France
EDOG - Centre Eugene Marquis Centre Regional de Lutte Contre Le Cancer - PPDS
Rennes, France
Institut de Cancerologie de l'Ouest
Saint-Herblain, France
Instituto de Investigacion Oncologica Vall d'Hebron (VHIO) - EPON
Barcelona, Spain
ICO l'Hospitalet - Hospital Duran i Reynals
Barcelona, Spain
Hospital General Universitario Gregorio Maranon
Madrid, Spain
START MADRID_Hospital Universitario Fundacion Jimenez Diaz
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.